Evidence Synthesis

COMPARATOR LANDSCAPE ASSESSMENTS
COMPARATOR LANDSCAPE ASSESSMENTS
We can identify the most appropriate comparator, assessing its importance and...
We can identify the most appropriate comparator, assessing its importance and relevance for HTA and reimbursement bodies
 EARLY TO LATE (E2L) PORTAL STRATEGY
EARLY TO LATE (E2L) PORTAL STRATEGY
E2L strategy development often consists of the planning and delivery of a detailed briefing…
E2L strategy development often consists of the planning and delivery of a detailed briefing pack to prepare Global Health Economics teams for internal discussions on whether to progress assets from Phase 1 studies to Phase 2 and beyond.
 EVIDENCE REVIEWS: GVDS/AMCP DOSSIERS
EVIDENCE REVIEWS: GVDS/AMCP DOSSIERS
A GVD (global value dossier) is a focused summary of the value proposition of a..
A GVD (global value dossier) is a focused summary of the value proposition of a therapeutic product with evidence-based key value messages. An AMCP (American College of Managed Care) dossier is a US verison of the GVD that adheres to the structure and domains prescribed by AMCP.
HTA & VALUE DEVELOPMENT
HTA & VALUE DEVELOPMENT
An HTA (Health Technology Assessment) is a multi-disciplinary field of policy…
An HTA (Health Technology Assessment) is a multi-disciplinary field of policy analysis that systematically evaluates the properties and effects of a health technology to inform decision making.

Payer value proposition development and construction involves the testing of potential value messages (VMs) associated with the clinical and economic evidence for a therapeutic and their further development with the client and associated advisors. It is also important to have a deep understanding of the potential reimbursement challenges and potential questions that may arise from payers and budget holders.

 KOL & PAYER ADVISORY BOARDS
KOL & PAYER ADVISORY BOARDS
Advisory boards are a means to elicit insights and inputs (strategy, tactics, value messages...
Advisory boards are a means to elicit insights and inputs (strategy, tactics, value messages, etc) from a diverse group of KOLs in the therapeutic area of interest, payers (ex-HTA, academics with expertise in the field, etc) and payer influencers. The boards can be in-person or virtual (eg iAdBoard), based on your project requirements and goals.
VALUE MESSAGE WORKSHOP
VALUE MESSAGE WORKSHOP
Value Messages form the skeleton of the GVD/AMCP dossier and link the evidentiary…

Value Messages form the skeleton of the GVD/AMCP dossier and link the evidentiary base to therapeutic value. We use the CID framework: Credibility, Important, and Differentiation of the value message to test potential messages with key stake holders. We can also undertake workshops to gain final consensus on VMs that will form the skeleton of the GVD
PURCHASE DECISION ANALYSIS
PURCHASE DECISION ANALYSIS
We use secondary research and our prior country specific knowledge to establish a…
We use secondary research and our country-specific knowledge to establish a framework of the market’s purchase decision process; identify the key stakeholders and inflection points in that process to identify price benchmarks and the potential target price range.
BACK
big-tw@2x
Tweet your
thoughts on Lifescience Dynamics

@LifeScienceDynamics

Terms & Conditions
© 2017 Lifescience Dynamics Limited